All In Biotech

Drug Trial Radar · NCT03934372

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jan 29, 2020

Primary completion

Feb 1, 2028

Study completion Feb 1, 2028

Sponsor

Sponsor type
Industry
First posted
May 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias, lymphomas, and solid tumors.

Conditions

  • Acute Myeloid Leukemia
  • Accelerated Phase Chronic Myeloid Leukemia
  • Blast Phase Chronic Myeloid Leukemia
  • Chronic Phase Chronic Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Lymphocytic Leukemia
  • Leukemia
  • Lymphoma
  • Solid Tumors

Interventions

  • PonatinibDrug

    Ponatinib administered as a tablet or age-appropriate formulation for pediatric participants according to age-based cohort assignment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of dose-limiting toxicitiesTime frame: 28 days
  2. Phase 2: Efficacy of ponatinib assessed by major cytogenetic response (MCyR) in participants with chronic-phase chronic myeloid leukemia (CP-CML)Time frame: 12 months
  3. Phase 2: Efficacy of ponatinib assessed by major hematologic response (MaHR) or major molecular response (MMR) in participants with BCR-ABL-positive leukemiasTime frame: 3 months
  4. Phase 2: Efficacy of ponatinib assessed by complete response (CR) in participants with leukemias other than BCR-ABL-positive leukemias to determine the efficacy of ponatinibTime frame: 6 months
  5. Phase 2: Efficacy of ponatinib assessed by incomplete complete response (iCR) in participants with leukemias other than BCR-ABL-positive leukemiasTime frame: 6 months
  6. Phase 2: Efficacy of ponatinib assessed by CR in participants with lymphomaTime frame: 6 months
  7. Phase 2: Efficacy of ponatinib assessed by overall response rate in participants with solid tumorsTime frame: 6 months

Locations

23 sites in 7 countries. Site status is shown where the registry gives one.

  • Ghent University Hospital

    Ghent, Belgium · Recruiting

  • Hopital Robert Debre

    Paris, France · Recruiting

  • Armand Trousseau Hospital

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France · Recruiting

  • Chu de Rennes - Hospital Sud

    Rennes, France · Completed

  • Aou Policlinico S. Orsola-Malpighi

    Bologna, Italy · Recruiting

  • Asst Degli Spedali Civili Di Brescia

    Brescia, Italy · Recruiting

  • Ospedale Pediatrico G. Gaslini

    Genova, Italy · Recruiting

  • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano

    Milan, Italy · Recruiting

  • University of Milano Bicocca

    Monza, Italy · Recruiting

  • Aorn Santobono Pausilipon

    Naples, Italy · Recruiting

  • Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo

    Pavia, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesu Irccs

    Rome, Italy · Recruiting

  • A.O.U Citta Della Salute E Della Scienza Di Torino Presidio Ospedaliero Infantile Regina Margherita

    Torino, Italy · Recruiting

  • Princess Maxima Center For Pediatric Oncology

    Utrecht, Netherlands · Recruiting

  • Hospital General Universitario Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hospital Sant Joan de Deu de Manresa

    Barcelona, Spain · Recruiting

  • Hospital Infantil Unversitario Nino Jesus

    Madrid, Spain · Recruiting

  • Hospital Universitari I Politecnic La Fe

    Valencia, Spain · Recruiting

  • Karolinska University Hospital Solna

    Stockholm, Sweden · Recruiting

  • Royal Hospital For Sick Children Yorkhill Glasgow

    Glasgow, United Kingdom · Recruiting

  • Alder Hey Childrens Nhs Foundation Trust

    Liverpool, United Kingdom · Recruiting

  • The Royal Marsden Nhs Foundation Trust - Sutton

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.